Biogen Inc
NASDAQ: BIIB
$159.36
+$1.67 (+1.1%)
Real Time Data Delayed 15 Min.
BIIB Articles
It seems Biogen's closely watched Alzheimer's drug candidate, aducanumab, has fallen short of analyst and investor expectations.
Published:
Earnings season is hitting its stride next week, and the health care sector, the biotech stocks in particular, have been on a roll for the past 12 months.
Published:
Last Updated:
Merrill Lynch sees Biogen returning to these heightened levels, with its pipeline acting as the primary catalyst.
Published:
Tuesday's top analyst upgrades, downgrades and initiations include Amazon.com, Biogen, GoPro, Intel, Micron Technology and SunPower.
Published:
24/7 Wall St. has reviewed the short interest in top biotech companies, without focusing on speculative companies.
Published:
Biogen announced on Friday that it is losing its head of research and development at the end of July.
Published:
The short interest data are out for the June 15 settlement date, and overall, short interest in the selected biotech stocks was mixed.
Published:
The May 29 short interest data have been compared with the previous figures, and for most of the selected biotech stocks, short interest has decreased.
Published:
The short interest data are out for the May 15 settlement date. Biotech companies are considered a riskier group of stocks.
Published:
The short interest data are out for the April 30 settlement date, and for most of the selected biotech stocks, short interest is down.
Published:
The higher the market goes, the harder it is for investors to know what to do. One good strategy is to always buy stocks that are the highest conviction picks at a Wall Street firm.
Published:
Last Updated:
The short interest data are out for the April 15 settlement date. 24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies.
Published:
Biogen reported disappointing first-quarter financials before the markets opened Friday.
Published:
Last Updated:
The March 31 short interest data have been compared with the March 13 figures, and for most of the selected biotech stocks, short interest has increased.
Published:
In a new report from RBC, while they think the selling and profit taking in biotechs could go on, they also hold fast that industry fundamentals are still very positive.
Published: